Podcasts

FDA Approval of 177Lu-PSMA-617 for Taxane-Naive mCRPC - Oliver Sartor

PSMA DC Trial: Lutetium + SBRT to Delay ADT in Oligometastatic Prostate Cancer - Oliver Sartor

Considerations for Patient Selection and Imaging in PSMA-Targeted Therapy - Tanya Dorff & Julie Graff

Integrating Lutetium-177-PSMA-617: Sequencing, Combinations, and Safety in Taxane-Naïve mCRPC - Michael Morris

Implementing Radioligand Therapy in a Urology Practice: A Discussion of Practical, Regulatory, and Team Considerations - Neal Shore

Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor

Pluvicto™ Expands to Pre-Chemotherapy Space for PSMA-Positive Prostate Cancer - Steven Finkelstein